Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Jung's paternity reveal exposes where Korea stands on extramarital babies

    Jung's paternity reveal exposes where Korea stands on extramarital babies
  2. 2

    Samsung entangled in legal risks amid calls for drastic reform

    Samsung entangled in legal risks amid calls for drastic reform
  3. 3

    Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul

    Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul
  4. 4

    [Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'

    [Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'
  5. 5

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
  1. 6

    [Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle

    [Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle
  2. 7

    Seoul blanketed by heaviest Nov. snow, with more expected

    Seoul blanketed by heaviest Nov. snow, with more expected
  3. 8

    K-pop fandoms wield growing influence over industry decisions

    K-pop fandoms wield growing influence over industry decisions
  4. 9

    [Graphic News] International marriages on rise in Korea

    [Graphic News] International marriages on rise in Korea
  5. 10

    Korea's auto industry braces for Trump’s massive tariffs in Mexico

    Korea's auto industry braces for Trump’s massive tariffs in Mexico
피터빈트

Samsung Bioepis’ Q1 biosimilar sales in Europe hit $205m

By Shim Woo-hyun

Published : April 23, 2021 - 17:14

    • Link copied

Samsung Bioepis’ three major autoimmune biosimilars: Benepali, Flixabi and Imraldi (Samsung Bioepis) Samsung Bioepis’ three major autoimmune biosimilars: Benepali, Flixabi and Imraldi (Samsung Bioepis)

Sales of biosimilars developed by Samsung Bioepis in Europe reached $205.1 million in the first quarter this year, the South Korean drugmaker said Friday.

Sales of Samsung Bioepis’ three major autoimmune biosimilars -- Benepali, Flixabi and Imraldi -- increased 3.9 percent on-quarter but decreased 6.3 percent on-year, the company said, citing an earnings report of its US partner Biogen released Thursday, local time.

Samsung Bioepis is a joint venture between Biogen and Samsung Group’s biopharmaceutical unit Samsung BioLogics.

“There was a sudden jump in sales during the first quarter last year as hospitals and wholesalers in Europe tried to stockpile products amid the COVID-19 pandemic,” a Samsung Bioepis official said, explaining the on-year decrease.

Samsung Bioepis said that Benepali accounted for the largest share in the European market by sales at 44 percent. Flixabi and Imraldi each accounted for over 10 percent in market share, the company added.

According to Samsung Bioepis, the total number of patients who have been treated with the company’s three biosimilars reached around 240,000 to date.

By Shim Woo-hyun (ws@heraldcorp.com)

More from Headlines